BlackRock launches UK Bitcoin ETP #CHAINREACTION https://t.co/CLtj8MycVb ...

Oct 20 Update:10 #Bitcoin ETFsNetFlow: -4,047 $BTC(-$449.51M)🔴#BlackRock outflows 2,520 $BTC($279.85M) and currently holds 802,311 $BTC($89.11B).9 #Ethereum ETFsNetFlow: -70,488 $ETH(-$284.28M)🔴#BlackRock outflows 38,109 $ETH($153.69M) and currently holds 4,014,825 $ETH($16.19B).https://t.co/zLDFRXeUpC ...

BlackRock Launches Bitcoin ETP for UK Retail Investors► https://t.co/seH9dTNNpo https://t.co/seH9dTNNpo ...

JUST IN: 🇬🇧 BlackRock's Bitcoin ETP to launch in the U.K. today https://t.co/tPSv2RFxke ...

BlackRock just deposited 12,000 $ETH($48.6M) to #CoinbasePrime an hour ago.https://t.co/qmuDIrPHc6 https://t.co/feCNkKrjPH ...

🇬🇧 NEW: BlackRock to launch its first Bitcoin-linked fund in the UK. https://t.co/25cPbitJzR ...

Group 1 - The SEC's approval of 3x- and 5x-leveraged ETFs is uncertain, as the director of investment management indicated compliance with the Derivatives Rule is unclear, which limits leverage to 2x [1] - A surge in risky product filings coincided with the federal government shutdown, leading to a backlog in the SEC's approval process, which typically has a 75-day window for disapproval [2] - Leveraged ETFs are viewed as trading tools rather than investments, with recommendations for strict position sizing and predefined time limits due to their inherent risks [3] Group 2 - Distribution challenges exist, as some trading platforms, like Vanguard, do not offer leveraged or inverse ETFs, while others, like Webull, note their use during volatile periods [4] - Numerous leveraged ETFs from various issuers are competing in the market, designed for intraday trading, which may lead to low asset retention and profitability concerns if they do not reach at least $100 million in scale [4]

😃🇬🇧🇬🇧🇬🇧Whale Insider (@WhaleInsider):JUST IN: 🇬🇧 BlackRock launches $BTC ETP in UK today. https://t.co/zFAnXbikKa ...

Core Insights - Rani Therapeutics Holdings experienced a significant stock surge of 248% to close at $1.64 following a collaboration announcement with Chugai Pharmaceutical [1] - The stock has increased by 222% over the past month, primarily due to investor enthusiasm surrounding its RaniPill technology, which allows for oral delivery of biologic drugs [2] Collaboration Details - The partnership with Chugai Pharmaceutical aims to develop an oral formulation utilizing RaniPill technology and Chugai's rare disease antibody, with potential deal value exceeding $1 billion if all milestones are achieved [2][4] - Rani will receive an upfront payment of $10 million and is eligible for up to $75 million in technology transfer and development milestones [3] - Additional potential earnings include up to $100 million in sales milestones and single-digit royalties on future sales, with Chugai having the option to expand the partnership to include up to five additional drug targets [4] Financing and Investor Interest - Concurrently with the Chugai deal, Rani announced a $60.3 million private placement financing led by Samsara BioCapital, with participation from several notable investors [5] - Despite being classified as a penny stock, Rani has attracted attention from major institutional investors, including Vanguard Group and BlackRock, indicating a notable level of confidence in the company [5]

JUST IN: 🇬🇧 BlackRock’s #Bitcoin ETP is set to list today on the London Stock Exchange for UK retail investors.Bullish 🚀 https://t.co/SWy09x6CJ8 ...